Expertise in
11
conditions

Xavier Roblin

Echirolles, FR 
Expertise in
11
conditions
Echirolles, FR 
OverviewLocationsClinical Research

Overview

Xavier Roblin practices in Echirolles, France. Mr. Roblin is highly rated in 11 conditions, according to our data. His top areas of expertise are Viral Gastroenteritis, Colitis, Crohn's Disease, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Echirolles, France
Other Locations
Saint-etienne-de-valoux, France
Avenue Albert Raimond, Saint-priest-la-vetre, 42270, France
France
Montpellier, France
St Etienne University Hospital
Saint-etienne, France
CHRU de Tours
Tours, France
Paris, France
Lyon, France
Amiens, France
Hotel Dieu
Nantes, France
Pierre-la-treiche, France
Bordeaux, France
University Hospital Of St Etienne, LINA EA 4624, Saint-jean-saint-germain, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Infliximab, Vedolizumab Injection
Study Phase: Phase 4
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up
Enrollment Status: Terminated
Publish Date: June 05, 2025
Intervention Type: Biological, Procedure
Study Drug: Blood sample
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Phase 4
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Enrollment Status: Terminated
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Valganciclovir
Study Phase: Phase 3
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Biological
Study Drugs: Prevenar 13, Pneumo 23
Study Phase: Phase 2
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 4
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Adalimumab
Study Phase: Phase 4
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Golimumab
Study Phase: Phase 4
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drugs: Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Study Phase: Phase 4
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: May 23, 2023
Intervention Type: Device, Procedure
Study Phase: Not Applicable
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: Infliximab, Azathioprine, Mercaptopurine, Methotrexate
Study Phase: Phase 4
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug, Diagnostic test, Biological
Study Drug: Golimumab
Study Phase: Phase 2
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Drug
Study Drugs: 5-ASA, Corticosteroids
Study Phase: Phase 3
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.
Enrollment Status: Completed
Publish Date: September 28, 2018
Intervention Type: Other
Study Phase: Not Applicable
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Enrollment Status: Completed
Publish Date: August 22, 2017
Intervention Type: Other
View 21 Less Clinical Trials

259 Total Publications

Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.
Journal: Journal of Crohn's & colitis
Published: August 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Roblin's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile